MCKESSON CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 569.6 USD | +1.54% |
|
+1.58% | +23.03% |
| May. 30 | McKesson Insider Sold Shares Worth $1,833,166, According to a Recent SEC Filing | MT |
| May. 29 | Baird Adjusts Price Target on McKesson to $679 From $671 | MT |
Financials (USD)
| Sales 2025 * | 358B | Sales 2026 * | 388B | Capitalization | 74.04B |
|---|---|---|---|---|---|
| Net income 2025 * | 3.72B | Net income 2026 * | 3.95B | EV / Sales 2025 * | 0.21 x |
| Net cash position 2025 * | 161M | Net cash position 2026 * | 3.01B | EV / Sales 2026 * | 0.18 x |
| P/E ratio 2025 * |
19.5
x | P/E ratio 2026 * |
17.8
x | Employees | 48,000 |
| Yield 2025 * |
0.47% | Yield 2026 * |
0.51% | Free-Float | 46.72% |
More Fundamentals
* Assessed data
More news
Latest transcript on McKesson Corporation
More recommendations
More press releases
More news
| 1 day | +1.54% | ||
| 1 week | +1.58% | ||
| 1 month | +6.03% | ||
| 3 months | +9.24% | ||
| 6 months | +21.05% | ||
| Current year | +23.03% |
1 week
547.01
570.59
1 month
520.49570.59
Current year
462.70570.59
1 year
383.82570.59
3 years
184.43570.59
5 years
112.60570.59
10 years
106.11570.59
| Managers | Title | Age | Since |
|---|---|---|---|
Brian Tyler
CEO | Chief Executive Officer | 57 | 11-12-31 |
| Director of Finance/CFO | 55 | 18-01-26 | |
Francisco Fraga
CTO | Chief Tech/Sci/R&D Officer | 51 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Donald Knauss
CHM | Chairman | 73 | 14-10-19 |
Webster Dunbar
BRD | Director/Board Member | 62 | 22-03-31 |
| Director/Board Member | 66 | 22-01-12 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.43% | 9 M€ | -.--% | ||
| 2.31% | 1,085 M€ | +9.05% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 569.6 | +1.54% | 1,165,435 |
| 24-05-30 | 561 | +0.37% | 599,204 |
| 24-05-29 | 558.9 | +1.75% | 1,037,458 |
| 24-05-28 | 549.3 | -2.05% | 1,144,951 |
| 24-05-24 | 560.7 | +0.48% | 512,352 |
Delayed Quote Nyse, May 31, 2024 at 04:00 pm EDT
More quotes
McKesson Corporation specializes in pharmaceutical product distribution. The group also offers technological services to healthcare companies. Net sales break down by activity as follows:
- distribution of pharmaceutical products (87%);
- distribution of medical and surgical products (4%);
- other (1.6%): primarily technology services and software sales.
The remaining net sales (7.4%) are from international activities.
Sector
Pharmaceuticals
Calendar
2024-06-02
- Ex-dividend day
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
569.6
USD
Average target price
589.5
USD
Spread / Average Target
+3.50%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +23.03% | 74.04B | |
| -1.52% | 24.18B | |
| +3.67% | 8.46B | |
| +8.55% | 8.34B | |
| -23.71% | 7.64B | |
| +15.20% | 5.33B | |
| -6.90% | 3.92B | |
| +2.68% | 4.12B | |
| +5.56% | 3.89B | |
| +18.80% | 3.54B |
- Stock Market
- Equities
- MCK Stock
